tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Catherine Novack, 8 are a BUY (88.89%), 1 are a HOLD (11.11%).
Analyst Catherine Novack, currently employed at JONESTRADING, carries an average stock price target met ratio of 41.67% that have a potential upside of 25.42% achieved within 140 days.
Catherine Novack’s has documented 16 price targets and ratings displayed on 4 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on DARE, Dare Bioscience at 16-Aug-2024.
Analyst best performing recommendations are on DARE (DARE BIOSCIENCE).
The best stock recommendation documented was for DARE (DARE BIOSCIENCE) at 5/16/2024. The price target of $5 was fulfilled within 6 days with a profit of $0.22 (4.21%) receiving and performance score of 7.02.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$12
$8.83 (278.55%)
$12
2 months 5 days ago
(17-Dec-2024)
13/16 (81.25%)
$8.81 (276.18%)
198
Buy
$13
$9.83 (310.09%)
$5
6 months 6 days ago
(16-Aug-2024)
2/3 (66.67%)
$9.43 (264.15%)
149
Hold
$4
6 months 8 days ago
(14-Aug-2024)
1/1 (100%)
$-15.44 (-79.42%)
660
Buy
$3
$-0.17 (-5.36%)
9 months 7 days ago
(15-May-2024)
2/2 (100%)
$-1.32 (-30.56%)
135
Buy
$2
$-1.17 (-36.91%)
$9
1 years 5 months 23 days ago
(30-Aug-2023)
1/2 (50%)
$-6.52 (-76.53%)
713
What Year was the first public recommendation made by Catherine Novack?
